NEONC TECHNOLOGIES HOLDINGS
NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing pioneering treatments for central nervous system diseases, focusing primarily on brain cancers such as glioblastoma. The company's innovative approaches seek to overcome the formidable challenge of delivering therapeutics across the blood-brain barrier, which has historically hindered effective treatment options.
Products & Team
NEO100
NEO100 is a highly purified form of perillyl alcohol (POH) that is administered intranasally. It is currently undergoing Phase II clinical trials specifically targeting patients with recurrent malignant glioma and malignant skull-based meningioma, aiming to provide an innovative solution in the treatment of these challenging CNS tumors.
NEO100 addresses the critical need for effective treatment options in patients with recurrent brain tumors, potentially offering improved drug delivery that can enhance therapeutic outcomes.
Many patients face significant challenges as traditional treatment methods often do not effectively target brain tumors due to the blood-brain barrier, leading to a critical need for innovative solutions.